Related Experiment Video
Updated: Jun 14, 2026
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Single-batch production of recombinant human polyclonal antibodies
Lars S Nielsen1, Alexandra Baer, Christian Müller
1Symphogen A/S, Elektrovej, Building 375, DK-2800, Lyngby, Denmark.
Molecular Biotechnology
|March 23, 2010
Summary
A new Sympress II technology using random integration in ECHO cells significantly increases recombinant polyclonal antibody (rpAb) production titers. This cost-efficient method maintains high reproducibility for single-batch manufacturing, suitable for niche indications.
Area of Science:
- Biotechnology
- Protein Engineering
- Cell Line Development
Background:
- Previous Sympress I technology utilized site-specific integration for recombinant polyclonal antibody (rpAb) production in CHO cells.
- Sympress I is industrial-scale but best suited for niche indications due to single-copy gene integration.
- There was a need to improve titers while maintaining cost-efficiency and reproducibility in single-batch manufacturing.
Purpose of the Study:
- To evaluate approaches for improving titers in single-batch rpAb manufacturing.
- To demonstrate the feasibility of a new expression process, Sympress II technology, for rpAb production.
- To assess the compositional stability and batch-to-batch reproducibility of rpAb produced by the new technology.
Main Methods:
- Development of ECHO cells, a CHO DG44 derivative, using random integration for enhanced productivity.
- Implementation of the Sympress II technology for single-batch rpAb manufacturing.
- Testing with two model systems, each comprising six target-specific antibodies.
Main Results:
- The Sympress II technology, utilizing random integration in ECHO cells, demonstrated significant titer increases.
- Compositional stability of rpAb produced by ECHO cells was comparable to site-specific integration.
- Batch-to-batch reproducibility was maintained at levels similar to the previous Sympress I technology.
Conclusions:
- The Sympress II technology is a feasible and improved method for single-batch rpAb manufacturing.
- Random integration in engineered ECHO cells offers higher titers and maintains high reproducibility.
- This advancement supports cost-efficient production for niche indications requiring rpAbs.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...